juststock/iStock via Getty Images Vivos Therapeutics ( NASDAQ: VVOS ) traded higher in the premarket on Thursday after announcing that a pilot program involving multiple medical facilities validated the assumptions behind its newly launched marketing and distribution model. The developer of Vivos CARE medical devices for obstructive sleep apnea (OSA) conducted the analysis using data from patients who visited seven dental offices and one ENT specialist office across several states over seven months. The company said that out of 99 patients seen by the providers under the program, 79% of newly diagnosed adult OSA patients preferred its oral appliance therapy over continuous positive airway pressure (CPAP) machines or no treatment options .
According to Vivos ( VVOS ), the results validated the newly launched model, through which the company intends to yield revenue by partnering with dentists and sleep therapy providers to make patients aware of OSA treatment options. More on Vivos Therapeutics Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Vivos Therapeutics Historical earnings data for Vivos Therapeutics Financial information for Vivos Therapeutics.